
Novo Nordisk Licenses Parkinson's Therapy to AI Startup, Shares Rise 24.9% in 30 Days
Novo Nordisk licensed its experimental Parkinson's cell therapy to AI-native biotech Cellular Intelligence and shut its internal cell therapy unit, refocusing on GLP-1 as its core franchise. Shares rose 24.9% over 30 days as investors backed the pivot. The move positions Europe's largest pharma company as a model for AI-outsourced drug R&D.


























